Receiving news on Viber
Today is the day “D” for one of the most successful pharmaceutical companies in the country, “Replek”. Throughout the day, the so-called split of the company’s ordinary shares is scheduled to take place. The company had already informed the public about the division some time ago, after the decision was made in April of this year. The registration of the share split in the Central Securities Depository will be initiated today, and for that reason, during today’s day, the company will…
Trading of Company Shares Temporarily Halted
Trading of the shares of this company on the stock exchange has been temporarily halted. The company announced the share split a few days ago, providing sensitive pricing information to investors. This decision was made at the Annual General Meeting held on April 25th of this year, regarding the division of common shares and a reduction in the nominal value of shares at a ratio of 1:10, which will take effect today. Therefore, trading of “Company X” shares will be halted today in order to allow for this process to take place.
Stock Split Announcement
Following a successful process and consultation with the Securities Commission and the Stock Exchange, trading of this company’s shares will resume next Monday. Here is what you need to know about the upcoming stock split.
The company has decided to split its common shares at a ratio of 1:10, meaning one common share will be divided into 10 new common shares. This will reduce the individual nominal value per share from €562.42 to €56.242. The stock split will not affect the company’s overall capital.
Reorganization of Company Shares
The company has decided to divide its shares into 259,200 common shares, each with a nominal value of 56.242 euros. Every shareholder who had a common share with a nominal value of 562.42 euros before the division will now receive 10 common shares with a nominal value of 56.242 euros each. The restructuring of the shares will not affect the company’s capital, as stated by the company.
Reasons for the Decision
Many are curious about why the company has taken this step and what their expectations are. It remains to be seen whether this move will bring any changes in the company’s operations or financial performance. Only time will tell how this reorganization will impact the company and its shareholders in the long run.
Increasing the Value of Company Stocks
The company has announced a future increase in the price of its stocks. They explain that their expectations are that by doing so, the company’s stocks will become more accessible to a wider range of shareholders, which in turn will lead to a more active capital market.
Company Strategy for Growth
The management team of “Replek AD” is focused on strengthening the company’s positions in both domestic and foreign markets, advancing their pharmaceutical portfolio, and increasing their workload. Their development strategy is yielding positive results, with continuous growth being observed. Recent financial
Positive Financial Results in the Pharmaceutical Sector
The latest financial results have shown a 20% increase in revenue from sales in the pharmaceutical sector in the first six months of 2024. This significant growth has been attributed to our dynamic and innovative approach, which has been well-received in the market.
Interest in our work is also growing among the investment community, with more investors showing interest in investing in our company, ‘Replek AD’. As management, we believe in the capital market and the opportunities it offers. In line with this, we have made the decision at the shareholders’ meeting to make our shares more accessible to different types of investors.
The Impact of Access on the Capital Market
Expanding access to the capital market not only stimulates market activity but also contributes to the development of companies listed on the Macedonian Stock Exchange. This was the response we received from “Replek”.
Following the announcement, the shares of “Replek” have seen an increase in price and a higher trading volume in recent days. Yesterday, the share of “Replek” closed at 125,000 denars per share on the regular market of the Stock Exchange, marking a 4.6% increase compared to the previous day. A smaller quantity of shares was sold yesterday, indicating a positive trend for the company.
Trading Activity of “Replek” Shares
On July 9th, during the second-to-last trading session of “Replek” shares, they were priced at 119,502.4 denars. What is interesting is that a significant amount of shares were traded on that day, with a total turnover of about 187 thousand euros. This may be related to the announced stock split, but there could be other reasons as well, given that “Replek” has long been one of the most traded stocks on the stock exchange.
Pharmaceutical?
Could it be that the high trading volume of “Replek” shares is due to the company’s involvement in the pharmaceutical industry? With such a large turnover, it seems that investors are showing interest in the company’s future prospects and growth potential. As one of the most traded stocks on the market, “Replek” seems to be attracting attention from various investors looking to capitalize on the pharmaceutical sector’s growth.
The Ownership Structure of Replek Company
After the departure of the Tugjarov family, the construction company “Replek” has a rather interesting and diverse ownership structure. The largest individual shareholder is Dusan Petkoski, who also manages the company and owns 12.19% of the share capital. His brother, Vladimir Petkoski, on the other hand, holds 6.33% of the capital.
The construction company “Nastel” owned by Zoran Azmanov holds 9.38% of the capital. The AD “Replek” itself holds 8.14% of the shares as its own stocks.
The pension fund “Sava” owns 6.4% of the capital, while the rest of the shares are held by various other shareholders.
Ownership structure of Sitko Antonio company
Currently, the company “Sitko Antonio” is owned by various shareholders, with 6.37% of the shares belonging to a new shareholder, the laboratory “Biotek”. The laboratory currently holds 6.3% of the company’s capital, having acquired it in a timely manner.
In addition to the laboratory, there are also several other small shareholders in the company, mainly domestic individuals and legal entities. The ownership structure of “Sitko Antonio” reflects a diverse range of stakeholders contributing to the company’s success.
